SAN FRANCISCO, May 3 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN - News) today announced that new data from the mild and moderate subgroups of Alzheimer's disease patients in the Company's six-month Phase 2 efficacy study of Dimebon(TM) showed that both subgroups were improved compared with placebo-treated patients on all five efficacy endpoints studied.
